Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
Status:
RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
Phase:
PHASE3
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)